From a clinical perspective, abdominal adiposity, and concurrent oral oestrogen therapy [both of which are associated with increased CRP levels (109, 110)] were shown to be independent predictors of subclinical inflammation, suggesting the need to consider the metabolic manifestations of PCOS and also its treatments (discussed later in this review) on long-term bone health (108). Here, CRP is linked to polycystic ovary syndrome.